Adil Daud, MD, a clinical professor in the Department of Medicine (Hematology/Oncology), at the University of California, San Francisco and the director of Melanoma Clinical Research at the UCSF Helen Diller Family Comprehensive Cancer Center

Adil Daud, MD

Combining the PD-1 inhibitor pembrolizumab (Keytruda) with intratumoral plasmid interkeukin-12 (IL-12; tavokinogene telseplasmid; Tavo) electroporation elicited clinical responses in patients with immunologically quiescent advanced melanoma, according to results of a single-arm, phase 2 study (NCT02493361) published in Clinical Cancer Research.1
... to read the full story

Source link